9 brokerages rate Pliant Therapeutics (NASDAQ:PLRX) as "Buy" with an average 1-year target price of $49.

9 brokerages covering Pliant Therapeutics (NASDAQ:PLRX) give an average rating of "Buy". The stock has received a consensus recommendation of "Buy" from analysts, with an average 1-year target price of $49. Analysts from Royal Bank of Canada, Needham & Company LLC, and HC Wainwright have recently issued "outperform", "buy", and "buy" ratings respectively, with price targets ranging from $38 to $54.

April 24, 2024
3 Articles

Further Reading